Didier Debieuvre1, Chrystèle Locher2, Bernard Asselain3, Charles Dayen4, Olivier Molinier5, Lionel Falchero6, Cécile Dujon7, Bertrand Delclaux8, Michel Grivaux2. 1. Groupe hospitalier de la région Mulhouse Sud-Alsace, hôpital Emile Muller, respiratory medicine department, 20, avenue du Dr Laënnec, BP 1370, 68070 Mulhouse cedex, France. Electronic address: debieuvred@ghrmsa.fr. 2. Hôpital de Meaux, respiratory medicine department, 6-8, rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France. 3. Hôpital Hôtel-Dieu, service d'oncologie médicale, 1, place du Parvis-de-Notre-Dame, 75004 Paris, France. 4. Centre hospitalier de Saint-Quentin, respiratory medicine department, 1, avenue Michel de l'hospital, 02321 Saint-Quentin, France. 5. Centre hospitalier du Mans, respiratory medicine department, avenue Rubillard, 72037 Le Mans, France. 6. Centre hospitalier de Villefranche-Sur-Saône, respiratory medicine department, 39, rue des Pavillons, 69400 Gleize, France. 7. Centre hospitalier de Versailles André Mignot, respiratory medicine department, 177, rue de Versailles, 78150 Le Chesnay, France. 8. Centre hospitalier de Troyes, respiratory medicine department, 101, avenue Anatole France, 10000 Troyes, France.
Abstract
BACKGROUND: Although improved during the last decades, the prognosis of lung cancer is poor. In 2000, the French College of general hospital respiratory physicians, conducted KBP-2000-CPHG, a prospective multicenter epidemiological study including all volunteer adult patients diagnosed for primary lung cancer; with the five-year survival as primary endpoint. The primary objective of KBP-2010-CPHG was to compare overall five-year survival data with KBP-2000-CPHG ones. MATERIAL AND METHODS: All consecutive patients≥18 years of age with primary lung cancer diagnosed between 1st January and 31st December 2010 were included. The KBP-2010-CPHG protocol was approved by the advisory committee on research information processing in the health field (CCTIRS) on November 19, 2009. RESULTS: Respectively, 5667 and 7051 patients were included in KBP-2000-CPHG and KBP-2010-CPHG. Five-year survival was improved: 12.7% [11.9%-13.5%] in 2010 versus 10.0% [9.2%-10.9%] in 2000 (P<0.001). Non-small-cell lung cancer showed improvement (13.8% [13.0%-14.8%] in 2010 versus 11.4% [10.5%-12.4%] in 2000; P<0.001); but not small-cell lung cancer (5.7% [4.4%-7.4%] in 2010 versus 3.3% [2.3%-4.7%] in 2000; P=0.56). The KBP-2010-CPHG study showed an overall 6% reduction in risk of death (HR=0.94 [0.89-0.98]; P=0.004). CONCLUSIONS: Survival of patients with lung cancer improved over a 10-year period. This improvement was slight and limited to non-small-cell lung cancer, possibly partly because of 2010 advances in diagnosis and targeted therapy.
BACKGROUND: Although improved during the last decades, the prognosis of lung cancer is poor. In 2000, the French College of general hospital respiratory physicians, conducted KBP-2000-CPHG, a prospective multicenter epidemiological study including all volunteer adult patients diagnosed for primary lung cancer; with the five-year survival as primary endpoint. The primary objective of KBP-2010-CPHG was to compare overall five-year survival data with KBP-2000-CPHG ones. MATERIAL AND METHODS: All consecutive patients≥18 years of age with primary lung cancer diagnosed between 1st January and 31st December 2010 were included. The KBP-2010-CPHG protocol was approved by the advisory committee on research information processing in the health field (CCTIRS) on November 19, 2009. RESULTS: Respectively, 5667 and 7051 patients were included in KBP-2000-CPHG and KBP-2010-CPHG. Five-year survival was improved: 12.7% [11.9%-13.5%] in 2010 versus 10.0% [9.2%-10.9%] in 2000 (P<0.001). Non-small-cell lung cancer showed improvement (13.8% [13.0%-14.8%] in 2010 versus 11.4% [10.5%-12.4%] in 2000; P<0.001); but not small-cell lung cancer (5.7% [4.4%-7.4%] in 2010 versus 3.3% [2.3%-4.7%] in 2000; P=0.56). The KBP-2010-CPHG study showed an overall 6% reduction in risk of death (HR=0.94 [0.89-0.98]; P=0.004). CONCLUSIONS: Survival of patients with lung cancer improved over a 10-year period. This improvement was slight and limited to non-small-cell lung cancer, possibly partly because of 2010 advances in diagnosis and targeted therapy.
Authors: Marta Soares; Luís Antunes; Patrícia Redondo; Marina Borges; Ruben Hermans; Dony Patel; Fiona Grimson; Robin Munro; Carlos Chaib; Laure Lacoin; Melinda Daumont; John R Penrod; John C O'Donnell; Maria José Bento; Francisco Rocha Gonçalves Journal: Lung Cancer Manag Date: 2021-02-19
Authors: Ana Casal-Mouriño; Alberto Ruano-Ravina; María Lorenzo-González; Ángeles Rodríguez-Martínez; Alexandra Giraldo-Osorio; Leonor Varela-Lema; Tara Pereiro-Brea; Juan Miguel Barros-Dios; Luis Valdés-Cuadrado; Mónica Pérez-Ríos Journal: Transl Lung Cancer Res Date: 2021-01